MindMaze Therapeutics Holding Stock
MindMaze Therapeutics Holding S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Zach W. Henderson
- Employees
- 10
- Market cap
- CHF26 M
- IPO
- 15/12/2025
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. Founded in 2012, the company is headquartered in Geneva, Switzerland. The product portfolio includes the MindPod system, which is a…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
MindMaze Therapeutics Holding stock: price history
1D
+5.0%
1W
+6.3%
1M
-1.6%
6M
-52.2%
YTD
-92.0%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
15/04/2027 (in 180 days)
Volatility around earnings
Not enough history for an assessment
Ask the agents about MindMaze Therapeutics Holding
Free float & liquidity
FREE FLOAT
79.7%
FLOAT SHARES
135,459,080
AVG. DAILY VOLUME (30D)
1,046,330
Dividends & Stock splits
Comparable stocks
Frequently asked questions about MindMaze Therapeutics Holding stock
What does MindMaze Therapeutics Holding do?
MindMaze Therapeutics Holding S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Zach W. Henderson, the company employs around 10 people.
The IPO was on 15/12/2025; the stock trades on SIX under the ticker MMTX.SW.
When does MindMaze Therapeutics Holding report next?
The next earnings date is 15/04/2027.
Does MindMaze Therapeutics Holding pay a dividend?
No, MindMaze Therapeutics Holding currently does not pay a dividend.
Which stocks are comparable to MindMaze Therapeutics Holding?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get MindMaze Therapeutics Holding stock analyzed?
Clicking "Analyze stock" lets five strategies assess MindMaze Therapeutics Holding against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.